JP2024519079A - 神経変性状態の治療のための組成物 - Google Patents

神経変性状態の治療のための組成物 Download PDF

Info

Publication number
JP2024519079A
JP2024519079A JP2023571820A JP2023571820A JP2024519079A JP 2024519079 A JP2024519079 A JP 2024519079A JP 2023571820 A JP2023571820 A JP 2023571820A JP 2023571820 A JP2023571820 A JP 2023571820A JP 2024519079 A JP2024519079 A JP 2024519079A
Authority
JP
Japan
Prior art keywords
triol
ethynylandrost
ene
pharmaceutical composition
motor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519079A5 (enExample
Inventor
クラレンス・ナサニエル・アレム
クリストファー・エル・リーディング
Original Assignee
バイオビー・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオビー・インコーポレイテッド filed Critical バイオビー・インコーポレイテッド
Publication of JP2024519079A publication Critical patent/JP2024519079A/ja
Publication of JP2024519079A5 publication Critical patent/JP2024519079A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023571820A 2021-05-18 2022-05-02 神経変性状態の治療のための組成物 Pending JP2024519079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189880P 2021-05-18 2021-05-18
US63/189,880 2021-05-18
PCT/US2022/027294 WO2022245532A1 (en) 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions

Publications (2)

Publication Number Publication Date
JP2024519079A true JP2024519079A (ja) 2024-05-08
JP2024519079A5 JP2024519079A5 (enExample) 2025-05-14

Family

ID=84141848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571820A Pending JP2024519079A (ja) 2021-05-18 2022-05-02 神経変性状態の治療のための組成物

Country Status (7)

Country Link
US (1) US20240108636A1 (enExample)
EP (1) EP4341271A4 (enExample)
JP (1) JP2024519079A (enExample)
AU (1) AU2022275684A1 (enExample)
CA (1) CA3218191A1 (enExample)
MX (1) MX2023013616A (enExample)
WO (1) WO2022245532A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054452A1 (en) * 2022-09-06 2024-03-14 Biovie Inc. Methods for the treatment of mild cognitive impairment
WO2025155561A1 (en) * 2024-01-16 2025-07-24 Biovie Inc. Methods of treating long covid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527986A (ja) * 2008-04-03 2011-11-10 ハーバー バイオサイエンシーズ，インコーポレイテッド 医薬の固体状態形態

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527986A (ja) * 2008-04-03 2011-11-10 ハーバー バイオサイエンシーズ，インコーポレイテッド 医薬の固体状態形態

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FABRIZIO STOCCHI ET AL.: ""How to optimize the treatment of early stage Parkinson’s disease"", TRANSLATIONAL NEURODEGENERATION, vol. 4, JPN6026021669, 25 February 2015 (2015-02-25), ISSN: 0005875119 *
FERDINANDO NICOLETTI ET AL.: ""17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impair", PARKINSON'S DISEASE, vol. 2012, JPN6026021671, 2012, pages 1 - 8, ISSN: 0005875117 *
PHILIPPENS, I. H. SR. ET AL.: ""Anti-Parkinsonand anti-L-Dopa induced dyskinesia efficacy of HE3286 in a MPTP non-humanprimate mod", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 43, JPN6026021670, 2013, ISSN: 0005875118 *

Also Published As

Publication number Publication date
AU2022275684A1 (en) 2023-11-16
WO2022245532A1 (en) 2022-11-24
EP4341271A1 (en) 2024-03-27
US20240108636A1 (en) 2024-04-04
EP4341271A4 (en) 2025-04-30
CA3218191A1 (en) 2022-11-24
MX2023013616A (es) 2024-01-17

Similar Documents

Publication Publication Date Title
US12083107B2 (en) Pharmaceutical compositions comprising glitazones and Nrf2 activators
Moncada et al. Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication
US20230321021A1 (en) Methods of normalizing amino acid metabolism
US20240108636A1 (en) Compositions for treatment of neurodegenerative conditions
AU2018329628B2 (en) Pridopidine for treating drug induced dyskinesias
EP2367529A1 (en) Composition for the use to treat alzheimer' s disease
Keating et al. Tolcapone: a review of its use in the management of Parkinson’s disease
US20130150346A1 (en) Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
KR20140146207A (ko) 운동 장애의 개선된 관리에 적합한 경구로 이용 가능한 약학적 제형
US20140112983A1 (en) Nitrite compositions and uses thereof
CN104334166A (zh) 用于预防和治疗精神、行为和认知障碍的药物组合物
Gong et al. 4, 4′-Dimethoxychalcone regulates redox homeostasis by targeting riboflavin metabolism in Parkinson's disease therapy
JP2023547479A (ja) 疾患の治療におけるヒト血清アルブミンの使用
AU4748100A (en) Glycine cleavage system inhibitors as potential antipsychotics
US11439613B2 (en) Levodopa fractionated dose composition and use
KR101851603B1 (ko) 신경염증제어를 통한 파킨슨 질환 예방 또는 치료용 조성물
US9504679B2 (en) Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20210308081A1 (en) Method and Composition for Enhancing the Quality and Benefits of Sleep
US20080076721A1 (en) Use of branched chain fatty acid amino acid salts and compositions thereof
Algantri et al. Neuroprotective Agents: Implications for Parkinson's Disease Treatment
TW201334776A (zh) 醫藥組成物
Gmiro et al. Comparison of the antiparkinson activity of levodopa, memantine, and guanidine-containing analogs of amantadine and memantine (IEM-2151 and IEM-2163) in rats with rotenone-induced parkinsonism
HK40052619A (en) Methods of normalizing amino acid metabolism
WO2007028770A1 (en) Monoamine neurotransmitter re-uptake inhibitors for neuroprotection in patients suffering from an advanced stage of a mental disease
KR20200140384A (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602